Structured evidence table for Saffron Social Anxiety Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Saffron Social Anxiety Randomized Trial | An increasing body of evidence suggests that these features may be modulated by sex-related differences. | 3 | Scenna Marta Sofia (2026) | Mitochondrial dysfunction and oxidative stress in autism spectrum disorder: pharmacological insights into natural antioxidants |
| Saffron Social Anxiety Randomized Trial | In addition, it can also be associated with other medical conditions including epilepsy, congenital cardiac defects, gastrointestinal (GI), immunological, endocrine/metabolic and sleep disorders, as well as psychiatric comorbidities like ADHD and anxiety. | 3 | Scenna Marta Sofia (2026) | Mitochondrial dysfunction and oxidative stress in autism spectrum disorder: pharmacological insights into natural antioxidants |
| Saffron Social Anxiety Randomized Trial | The role of environmental factors in ASD became evident with the observation that advanced paternal and maternal age is associated with an increased likelihood of having a child with ASD (). | 3 | Scenna Marta Sofia (2026) | Mitochondrial dysfunction and oxidative stress in autism spectrum disorder: pharmacological insights into natural antioxidants |
| Saffron Social Anxiety Randomized Trial | Lord et al., 2018 Faja and Dawson, 2017 Dellapiazza et al., 2022 Napolitano et al., 2022 Figure 1 Autism spectrum disorder (ASD) is a lifelong neurodevelopmental disorder characterized by deficits in social communication and interaction, as well as restricted and repetitive patterns of behavior, interests, and activities, often accompanied by atypical sensory-motor responses (). | 3 | Scenna Marta Sofia (2026) | Mitochondrial dysfunction and oxidative stress in autism spectrum disorder: pharmacological insights into natural antioxidants |
| Saffron Social Anxiety Randomized Trial | 73% of participants agreed that they found the app easy to use overall and that an app is a good format for offering anxiety support to autistic people. | 4 | Oakley B (2025) | Feasibility Study of a Novel App-Based Anxiety Intervention for Autistic People. |
| Saffron Social Anxiety Randomized Trial | We found that an autism-adapted app-based anxiety management tool is acceptable to the community and associated with reduced anxiety symptom severity in autistic adults, on average. | 4 | Oakley B (2025) | Feasibility Study of a Novel App-Based Anxiety Intervention for Autistic People. |
| Saffron Social Anxiety Randomized Trial | At least 50% of autistic people experience clinically relevant anxiety symptoms. | 4 | Oakley B (2025) | Feasibility Study of a Novel App-Based Anxiety Intervention for Autistic People. |
| Saffron Social Anxiety Randomized Trial | However, reasons for elevated rates of anxiety in autism remain poorly understood and there is a high unmet need for novel and adapted therapies for anxiety that are accessible to autistic people. | 4 | Oakley B (2025) | Feasibility Study of a Novel App-Based Anxiety Intervention for Autistic People. |
Source documents